Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy

The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate antibody levels and how to combine them with other clin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical journal of the American Society of Nephrology 2023-10, Vol.18 (10), p.1283-1293
Hauptverfasser:	Barbour, Sean J, Fervenza, Fernando C, Induruwage, Dilshani, Brenchley, Paul E, Rovin, Brad, Hladunewich, Michelle A, Reich, Heather N, Lafayette, Richard, Aslam, Nabeel, Appel, Gerald B, Zand, Ladan, Kiryluk, Krzysztof, Liu, Lili, Cattran, Daniel C
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumins Autoantibodies Creatinine Cyclosporine - therapeutic use Glomerular and Tubulointerstitial Diseases Glomerulonephritis, Membranous - drug therapy Humans Original Receptors, Phospholipase A2 Risk Factors Rituximab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!